Radiotherapy and combined modality approaches in localised prostate cancer

Affiliations

Review

D P Dearnaley. Eur J Cancer. 2001 Oct.

. 2001 Oct:37 Suppl 7:S137-45.

doi: 10.1016/s0959-8049(01)80015-0.

¹ The Institute of Cancer Research and The Royal Marsden NHS Trust, Academic Unit of Radiotherapy, Sutton, Surrey, UK.

No abstract available

Cited by

Assessing of integration of ionizing radiation with Radachlorin-PDT on MCF-7 breast cancer cell treatment.
Ghoodarzi R, Changizi V, Montazerabadi AR, Eyvazzadaeh N. Ghoodarzi R, et al. Lasers Med Sci. 2016 Feb;31(2):213-9. doi: 10.1007/s10103-015-1844-0. Epub 2015 Dec 21. Lasers Med Sci. 2016. PMID: 26690358
Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.
Hirano D, Nagane Y, Satoh K, Mochida J, Sugimoto S, Ichinose T, Takahashi S, Maebayashi T, Saitoh T. Hirano D, et al. Int Urol Nephrol. 2010 Mar;42(1):81-8. doi: 10.1007/s11255-009-9580-7. Epub 2009 May 16. Int Urol Nephrol. 2010. PMID: 19449118 Clinical Trial.
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, Gadd J, Warrington A, Bidmead M, Horwich A. Dearnaley DP, et al. Br J Cancer. 2005 Feb 14;92(3):488-98. doi: 10.1038/sj.bjc.6602301. Br J Cancer. 2005. PMID: 15685244 Free PMC article. Clinical Trial.